Literature DB >> 35037979

[Guideline-based thermal ablation of hepatocellular carcinoma].

Andreas H Mahnken1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is fifth most common cancer worldwide. The German S3 guideline on the diagnosis and the treatment of hepatocellular and biliary carcinoma was recently revised.
OBJECTIVE: Determination of the current status of thermal ablation in HCC according to the German S3 guideline.
MATERIALS AND METHODS: Based on the current guideline and a selective literature search, the current status on indication and application of thermal ablation in HCC was revisited.
RESULTS: Radiofrequency ablation (RFA) and microwave ablation (MWA) provide similar survival when compared with surgery. Accordingly, RFA und MWA are considered first-line treatments for HCCs ≤ 3 cm in cirrhotic livers. For HCCs with diameters of 3-5 cm, a combination of transarterial chemoembolization and thermal ablation is recommended.
CONCLUSION: The current S3 guideline on diagnosis and treatment of HCC comprises relevant changes regarding thermal ablation in HCC. The overall role of interventional oncology procedures in the treatment of HCC was reinforced.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Interventional radiology; Liver cancer; Microwave ablation; Radiofrequency ablation; Thermal ablation

Mesh:

Year:  2022        PMID: 35037979     DOI: 10.1007/s00117-021-00960-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.

Authors:  Rusi Zhang; Lujun Shen; Long Zhao; Zhaoming Guan; Qifeng Chen; Wang Li
Journal:  Diagn Interv Radiol       Date:  2018-07       Impact factor: 2.630

2.  [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial].

Authors:  Ming-de Lü; Ming Kuang; Li-jian Liang; Xiao-yan Xie; Bao-gang Peng; Guang-jian Liu; Dong-ming Li; Jia-ming Lai; Shao-qiang Li
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2006-03-28

Review 3.  Controversies in criteria for liver transplantation in hepatocellular carcinoma.

Authors:  Neehar D Parikh; Adam Yopp; Amit G Singal
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.